Related Experiment Video
Updated: Jan 25, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
Review: Therapeutic potential of carbonic anhydrase inhibitors
Shafiqur Rahman1, Sumbal Bibi1, Tariq Javed2
1Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan.
Abstract:
Enzymes are biological catalyst involve in different biochemical reactions. But over activation of these biomolecules can cause disease thus different inhibitors and knockout therapies are use in current clinical practice. Carbonic anhydrases (CAs), a group of ubiquitously expressed metalloenzymes, are involved in numerous physiological and pathological processes, including gluconeogenesis, lipogenesis, ureagenesis, tumorigenicity and the growth and virulence of various pathogens. In addition to the established role of CA inhibitors (CAIs) as diuretics and antiglaucoma drugs, it has recently emerged that CAIs could have potential as novel anti-obesity, anticancer and anti-infective drugs. Furthermore, recent studies suggest that CA activation may provide a novel therapy for Alzheimer's disease. This article discusses the biological rationale for the novel uses of inhibitors or activators of CA activity in multiple diseases, and highlights progress in the development of specific modulators of the relevant CA isoforms, some of which are now being evaluated in clinical trials.
Insights
Carbonic anhydrases (CAs) are enzymes with roles in many diseases. Inhibitors and activators targeting specific CA isoforms show promise for treating obesity, cancer, infections, and Alzheimer's disease.
Area of Science:
- Biochemistry
- Enzymology
- Pharmacology
Background:
- Enzymes act as biological catalysts, but their overactivation can lead to disease.
- Carbonic anhydrases (CAs) are metalloenzymes involved in essential physiological and pathological processes.
- Current therapies include inhibitors and knockout strategies for enzyme-related diseases.
Purpose of the Study:
- To discuss the biological basis for novel therapeutic applications of carbonic anhydrase modulators.
- To highlight advancements in developing specific modulators for carbonic anhydrase isoforms.
- To explore the potential of CA inhibitors and activators in treating various diseases.
Main Methods:
- Review of existing literature on carbonic anhydrase function and inhibition/activation.
- Analysis of established and emerging therapeutic roles of CA modulators.
- Discussion of ongoing clinical trials for CA-targeted therapies.
Main Results:
- Carbonic anhydrase inhibitors (CAIs) are established diuretics and antiglaucoma agents.
- Emerging evidence suggests CAIs as potential treatments for obesity, cancer, and infections.
- CA activation is being explored as a novel therapy for Alzheimer's disease.
Conclusions:
- Modulators of carbonic anhydrase activity offer promising therapeutic avenues for diverse diseases.
- Targeting specific CA isoforms is crucial for developing effective treatments.
- Several CA modulators are progressing through clinical trials, indicating significant therapeutic potential.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
The Carbon Cycle
Carbon Skeletons
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...

